Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system to maximize viral clearance.
Influenza (“the flu”) is a contagious viral infection that can cause mild to severe illness, sometimes resulting in death. While today’s flu vaccines are credited with significant public health benefits and offer our current best defense, only 49% of Americans get an annual flu vaccine1, and a majority of those people do not respond. As a result, most Americans are still at risk of getting the flu yearly. In fact, during the 2018-19 flu season, a staggering 71% did not respond to vaccination and 34,200 people died of flu-related illness in the US alone. The estimated average annual total economic burden of influenza to the healthcare system and society is more than $11.2 billion. For more information about influenza, visit the CDC website.
ANTIVIRAL CONJUGATES (AVCs) FOR INFLUENZA PREVENTION: CD377 and CD388
Cidara’s goal is to develop its lead flu AVCs, CD377 and CD388, to achieve universal prevention of seasonal and pandemic influenza with a single dose. Antiviral conjugates are not vaccines or monoclonal antibodies. Their targeting domains are small molecule antivirals that bind to a highly conserved target on the influenza cell surface, which is essential for viral proliferation and enables universal influenza coverage. These long-acting, bispecific AVCs are designed to directly inhibit viral proliferation while simultaneously directing immune-mediated clearance of the virus. The two distinct and complementary mechanisms are designed to maximize antiviral activity of AVCs.
Flu AVCs have the potential to offer significant advantages over current flu vaccines:
- True universal protection, against all influenza strains and for all people, including those with a compromised immune system
- Near-immediate protective effects
CD388 is a longer acting version of CD377, and differs only in its effector domain, a proprietary variant of a human antibody fragment (Fc). Cidara is conducting IND-enabling studies in order to begin Phase 1 clinical trials in its influenza program.
Preclinical studies demonstrate:
ANTIVIRAL CONJUGATES (AVCs) FOR INFLUENZA TREATMENT: CD377 and CD388
There are currently four drugs recommended by the CDC for treating influenza. All have one or more of the following limitations:
Short half-life and limited efficacy window
Susceptibility to resistance
Limited routes of administration
Cidara’s flu AVCs for flu treatment are designed to disrupt the current standard of care. The targeting domains of flu AVCs are potent small molecule antivirals that bind to a highly conserved target on the cell surface of all influenza viral strains which is essential for viral proliferation. With this mechanism, AVCs have the potential for fast-acting universal coverage of influenza A and B, including all major clinically characterized drug-resistant strains.
Cidara is conducting IND-enabling studies in order to begin Phase 1 clinical trials in its influenza program.
Preclinical studies demonstrate: